Anzeige
Mehr »
Login
Donnerstag, 03.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QF49 | ISIN: US45674E1091 | Ticker-Symbol: 6JH
Tradegate
01.04.25
15:33 Uhr
0,162 Euro
+0,003
+1,89 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IN8BIO INC Chart 1 Jahr
5-Tage-Chart
IN8BIO INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1490,15322:58
0,1420,15222:00

Aktuelle News zur IN8BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.03.IN8bio GAAP EPS of -$0.085
13.03.IN8BIO, INC. - S-8, Securities to be offered to employees in employee benefit plans4
IN8BIO Aktie jetzt für 0€ handeln
13.03.IN8bio, Inc: IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights149Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML)...
► Artikel lesen
13.03.IN8BIO, INC. - 10-K, Annual Report1
13.03.IN8BIO, INC. - 8-K, Current Report2
03.03.IN8bio, Inc: IN8bio Announces Advanced Gamma-Delta T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases184Proprietary platform represents the first known approach capable of sustained gamma-delta T cell expansion, eliminating target cells with robust potencyINB-619, a next generation gamma-delta TCE targeting...
► Artikel lesen
03.03.IN8BIO, INC. - 8-K, Current Report1
14.02.IN8bio reports promising phase 1 results for leukemia therapy6
14.02.IN8bio, Inc: IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML188NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday...
► Artikel lesen
11.02.Jones Trading lifts IN8bio stock rating to Buy, sets $1.20 target6
11.02.IN8bio, Inc: IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients235100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated...
► Artikel lesen
11.02.IN8BIO, INC. - 8-K, Current Report1
10.12.24IN8bio, Inc: IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting99INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up...
► Artikel lesen
10.12.24IN8BIO, INC. - 8-K, Current Report-
25.11.24IN8bio reports promising glioblastoma trial results1
25.11.24IN8bio, Inc: IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting14150% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median overall survival (OS) from standard-of-care Stupp regimen while none of the patients who...
► Artikel lesen
25.11.24IN8BIO, INC. - 8-K, Current Report1
13.11.24IN8bio GAAP EPS of -$0.152
12.11.24IN8bio, Inc: IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights300Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future...
► Artikel lesen
12.11.24IN8BIO, INC. - 10-Q, Quarterly Report1
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1